MarketPulse

respiratory care

4 articles
The Motley FoolThe Motley Fool··Selena Maranjian

ResMed Eyes Growth Despite Healthcare Headwinds With Valuation Upside

ResMed trades at a 25% valuation discount despite 11% revenue growth and expanding digital health operations in 140+ countries, though Medicare reimbursement risks persist.
RMDstock valuationgrowth stocks
BenzingaBenzinga··Globe Newswire

Quipt Home Medical Approved for US$3.65/Share Buyout, Delisting Expected by March 2026

Quipt Home Medical receives final court approval for US$3.65/share acquisition by Kingswood and Forager Capital affiliates, with delisting expected by March 2026.
QIPTacquisitiondelisting
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quipt Home Medical Approved for US$3.65/Share Buyout, Delisting Expected by March 2026

Quipt Home Medical gains final court approval for US$3.65/share acquisition by Kingswood and Forager Capital affiliates, with delisting expected by March 2026.
QIPTacquisitiondelisting
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quipt Home Medical Shareholders Overwhelmingly Approve $3.65/Share Buyout

Quipt Home Medical shareholders voted 98.9% in favor of acquisition by Kingswood and Forager Capital for US$3.65 per share, with court approval expected March 5, 2026.
QIPTacquisitionregulatory approval